Valganciclovir

Usual Dosing (Adults)

Adult Patients With Normal Renal Function

Treatment of CMV Retinitis:
Induction: The recommended dose is 900 mg (two 450 mg tablets) twice a day for 21 days.
Maintenance: Following induction treatment, or in adult patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once a day.

Prevention of CMV Disease:
For adult patients who have received a heart or kidney-pancreas transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 100 days post-transplantation.

For adult patients who have received a kidney transplant, the recommended dose is 900 mg (two 450 mg tablets) once a day starting within 10 days of transplantation until 200 days post-transplantation.

Renal Dosing

[> 60 ml/min]: usual dosages.

[40-59 ml/min]: Induction: 450mg bid. Maint: 450mg qd.

[25-39 ml/min]: Induction: 450mg po qd. Maint: 450 mg q2 days.

[10-24 ml/min]: Induction: 450mg po q2 days. Maint: 450mg twice weekly.

Hemodialysis

Hemodialysis:
Manufacturer: Valcyte should not be prescribed to patients receiving hemodialysis.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.